HOUSTON, Nov. 16, 2021 /PRNewswire/ -- CNS
Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the
"Company"), a biopharmaceutical company specializing in the
development of novel treatments for primary and metastatic cancers
in the brain and central nervous system, today announced that
John Climaco, Chief Executive
Officer and Sandra L. Silberman, MD,
PhD Chief Medical Officer will participate in the Virtual Investor
Roundtable Event on Thursday, November 18,
2021 at 9:00 AM ET.
As part of the virtual event, the Company will provide a brief
presentation, followed by a moderated Roundtable discussion and an
interactive Q&A session. In addition to the moderated portion
of the event, all investors and interested parties will have the
opportunity to submit questions live during the event. Interested
parties may also pre-submit questions in advance of the live event,
which can be sent via the conference website at
virtualinvestorco.com. The Company will answer as many questions as
possible during the event.
A live video webcast of the Roundtable Event will be
available on the Events page of the Investors section of
the Company's website (cnspharma.com). A webcast replay will be
available two hours following the live presentation and will be
accessible for one year.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company
developing a pipeline of anti-cancer drug candidates for the
treatment of primary and metastatic cancers of the brain and
central nervous system. The Company's lead drug candidate,
Berubicin, is a novel anthracycline and the first anthracycline to
appear to cross the blood-brain barrier. Berubicin is currently in
development for the treatment of a number of serious brain and CNS
oncology indications including glioblastoma multiforme (GBM), an
aggressive and incurable form of brain cancer.
Additionally, the Company is advancing the development of its
WP1244 drug technology, which utilizes anthracycline and
distamycin-based scaffolds to create small molecule agents and is
believed to be 500x more potent than daunorubicin in inhibiting
tumor cell proliferation. Preclinical studies of WP1244
demonstrated high uptake in the brain with antitumor activity. CNS
Pharmaceuticals is evaluating the use of WP1244 in the treatment of
brain cancers, pancreatic, ovarian, and lymphomas.
For more information, please visit www.CNSPharma.com, and
connect with the Company on Twitter, Facebook, and LinkedIn.
View original content to download
SOURCE CNS Pharmaceuticals, Inc.